Chameleon Pharma Consulting with 50 completed projects in the CIS&CEE Region!

The pharma consulting expert for the health care market in CIS and Eastern Europe - Chameleon Pharma Consulting has competed 50 projects within the last years.
The company celebrated this successful record during the participation of the Expopharm 2011.

(firmenpresse) - Furthermore, Andreas Masel has joined the management. Together with Reiner Christensen, he is responsible for the company’s key clients and for advising on the strategic development in the CIS and Eastern European markets.

Part of the core business of Chameleon Pharma Consulting, besides M&A and due diligence, is the search for highly-productive pharma partners in the CEE & CIS markets for companies from West-Europe, Asia and the USA.

… We are very proud of also advising many Russian, Ukrainian etc. companies in the CIS markets on their expansion plans…
Furthermore the company successfully advises local pharma companies in Russia, Ukraine, Kazakhstan, Poland, Romania, etc. on the expansion in the GUS and East-Europe markets, as well as on acquiring financing and possible investors.

With Andreas Masel, the managament’s Pharma expertise is expanding to over 50 years of work experience in the CIS and Eastern Europe region. Beforehand Masel worked in the international magament of, amongst others, Stada, Berlin Chemie, Nycomed, Gehe, Jenapharm and Azupharma.

…Our long-standing 50 years network in the CIS&CEE Region is a core asset of us…
“Andreas Masel profitably complements our network with his long-standing contacts to Russia, Ukraine, Romania”, explains Reiner Christensen. This is one of our core assets. Christensen is himself well networked in the CIS and East Europe regions due to management positions at Merck, Höchst, Ferrosan, Richard Bittner, and Omega Pharma.

As an expert for export and international business relations Masel was previously in charge of the acquisition of Nizpharm for Stada in Russia, of establishing business relations in Eastern Europe and the CIS-Countries for Berlin Chemie, as well as international export sales of Nycomed particularly in Romania, Hungary, Poland and Bulgaria.

“In Russia and Eastern Europe good co-operations emerge from personal relationships and mutual trust”, Andreas Masel explains. They can’t be built during one or two trips to the Region. Above all it requires lasting and not only business based conversations.



…We are often asked to participate in our client’s new strategy to gain more market share in the
growing eastern markets…
When we meet our clients first they mostly do not recognize how much growth potential the CIS /CEE Region offers. “After the first project we are often asked to participate in the company new strategy update to gain more market share in the growing Eastern markets” says Mr. Christensen.

Before consulting for Chameleon Pharma Consulting he was responsible for the sales & EBIT of international Pharma and OTC enterprises in the CIS and Eastern Europe region. He was and is specialized in setting up business relations in the health care and Pharma market concerning medical devices, RX, OTC, Food supplements and cosmetic products.


Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: ChameleonPharma
Datum: 09.11.2011 - 15:00 Uhr
Sprache: Deutsch
News-ID 516637
Anzahl Zeichen: 3309

Kontakt-Informationen:

Kategorie:

Wirtschaft (allg.)

Meldungsart: Erfolgsprojekt
Versandart: Veröffentlichung
Freigabedatum: 07.11.2011

Diese Pressemitteilung wurde bisher 520 mal aufgerufen.

Die TRIUMPH-Märkte bieten Potenzial für mittelständische OTC- und Pharma-Unternehmen. ...
Gerade auch mittelständische Unternehmen sollten heute international nach Möglichkeiten Ausschau halten, um zusätzliche Marktanteile und Zusatzgewinne zu generieren. Da mit dem Launch in den Emerging Markets große Investitionen und Risiken verbunden sind, ist eine gründliche Marktanalyse ratsam

CHAMELEON PHARMA CONSULTING auf der EXPOPHARM ...
Chameleon Pharama Consulting ist ein junges Unternehmen, das sich aber rasch als zuverlässiger und erfolgreicher Partner für die Markterweiterung im Gesundheitsbereich etabliert hat. 60 erfolgreich abgeschlossene Consulting-Projekte in den letzten drei Jahren – diese Zahlen sprechen für sich.

Polfarma increased its stake in Russian pharma company ...
The joint-stock company Polfarma Pharmaceutical Factory increased its stake in OJSC Integrated Chemical and Pharmaceutical Enterprise Akrikin from 72.54% to 98.17%. Akrikhin is the fifth largest local producer by revenue 2010 and one of the fastest growing pharmaceutical companies on the Russian

Weitere Mitteilungen von Chameleon Pharma Consulting

Agreement on the mutual recognition procedure of registration certificates for medicines ...
The Commission of the Custom Unions – Russia, Belarus and Kazakhstan – is currently working on creating new conditions for mutual recognition of registration certificates for medical products in compliance with Good Manufacturing Practice (GMP). "The introduction of the agreement on the mu

The EU and Russia agree on mutual recognition of clinical trials ...
"We have to soon sign a document that would address issues concerned the mutual recognition of clinical trials," said the Minister after his meeting with EU Commissioner of Health John Dalli. The goal is: • To regulate standards and practices of clinical research • If products

Ukraine: No limit for drug and OTC advertising ...
According to news.liga.net, the project planned to allow the placement of advertising and distribution of drugs only • In specialized publications intended for medical facilities and doctors. • By placing advertisements in medical institutions and pharmacies. • And also proposed to exten

Compared to 2011 the purchase of drugs in 2012 via the program “7 nostages” will increase by 13% ...
Compared to 2011 in 2012 the purchase of drugs for treatments like hematopoietic and related tissues, hemophilia, multiple sclerosis, as well as post-transplant organs and other tissues, will increase by 13%. •The budget allocation for these purposes in 2012 - 2014 will amount up to 54.17 billi